

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|--------------------------------|
| Name of entity | Melodiol Global Health Limited |
| ABN | 89 609 406 911 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|-----------------|
| Name of Director | William Lay |
| Date of last notice | 3 November 2023 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|--|
| Direct or indirect interest | Indirect |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | Noble House Consulting Ltd - a director-related entity. |
| Date of change | 13 November 2023 |
| No. of securities held prior to change | 42,500,000 Fully Paid Ordinary Shares 1,666,667 ME1O Options (\$0.25, 2/11/2024) 10,000,000 ME1OPT41 Options (\$0.18, 6/09/2024) 10,000,000 ME1OPT42 Options (\$0.25, 6/09/2024) 2,500,000 ME1OD Options (\$0.08, 31/01/2027) 10,000,000 ME1OPT56 Options (\$0.20, 17/01/2024) 7,500,000 ME1PERR51 Performance Rights 50,000,000 ME1PERR52 Performance Rights |
| Class | ME1OE Listed Options (\$0.006, expiring 13/11/2028) |
| Number acquired | 2,125,000 |

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

| | |
|---|---|
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | Issued for nil consideration under the bonus option issue made to all eligible shareholders. Refer to Prospectus released 31 October 2023 (and Supplementary Prospectus released 6 November 2023) for further information. |
| No. of securities held after change | 42,500,000 Fully Paid Ordinary Shares 1,666,667 ME1O Options (\$0.25, 2/11/2024) 10,000,000 ME1OPT41 Options (\$0.18, 6/09/2024) 10,000,000 ME1OPT42 Options (\$0.25, 6/09/2024) 2,500,000 ME1OD Options (\$0.08, 31/01/2027) 10,000,000 ME1OPT56 Options (\$0.20, 17/01/2024) 7,500,000 ME1PERR51 Performance Rights 50,000,000 ME1PERR52 Performance Rights 2,125,000 ME1OE Listed Options (\$0.006, expiring 13/11/2028) |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issued under the bonus option issue made to all eligible shareholders. Refer to Prospectus released 31 October 2023 (and Supplementary Prospectus released 6 November 2023) for further information. |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|-----|
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|-----------------------|-----|
| Interest after change | N/A |
|-----------------------|-----|

Part 3 – +Closed period

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|--------------------------------|
| Name of entity | Melodiol Global Health Limited |
| ABN | 89 609 406 911 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|-----------------|
| Name of Director | Bruce Linton |
| Date of last notice | 3 November 2023 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|---|
| Direct or indirect interest | Direct and Indirect |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | HSBC Custody Nominees (Australia) Limited and Canaccord Genuity Corp <Bruce Linton A/C> are nominee entities for director, Bruce Linton. |
| Date of change | (a) 13 November 2023 (b) 16 November 2023 |
| No. of securities held prior to change | <u>Direct:</u> 8,144,097 Fully Paid Ordinary Shares 30,000,000 ME1OPT33 Options (\$0.039, 23/12/2025) <u>Indirect:</u> <i>HSBC Custody Nominees (Australia) Limited</i> 5,000,000 Fully Paid Ordinary Shares 5,000,000 ME1OD Options (\$0.08, 31/01/2027) <i>Canaccord Genuity Corp <Bruce Linton A/C></i> 10,000,000 ME1OPT46 Options (\$0.09, 17/01/2024) |

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

| | |
|---|--|
| Class | ME1OE Listed Options (\$0.006, expiring 13/11/2028) ME1OD Listed Options (\$0.08, 31/01/2027) |
| Number acquired | (a) 657,204 ME1OE Listed Options (\$0.006, expiring 13/11/2028) (b) 2,732,213 ME1OD Listed Options (\$0.08, 31/01/2027) |
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | (a) ME1OE Options issued for nil consideration under the bonus option issue made to all eligible shareholders. Refer to Prospectus released 31 October 2023 (and Supplementary Prospectus released 6 November 2023) for further information. (b) ME1OD Options issued free-attaching to Shares issued in lieu of Director Fees. Refer to Resolution 11 of the Notice of Meeting dated 12 September 2023. |
| No. of securities held after change | <u>Direct:</u> 8,144,097 Fully Paid Ordinary Shares 30,000,000 ME1OPT33 Options (\$0.039, 23/12/2025) 2,732,213 ME1OD Listed Options (\$0.08, 31/01/2027) 407,204 ME1OE Listed Options (\$0.006, expiring 13/11/2028) <u>Indirect:</u> <i>HSBC Custody Nominees (Australia) Limited</i> 5,000,000 Fully Paid Ordinary Shares 5,000,000 ME1OD Options (\$0.08, 31/01/2027) 250,000 ME1OE Listed Options (\$0.006, expiring 13/11/2028) <i>Canaccord Genuity Corp <Bruce Linton A/C></i> 10,000,000 ME1OPT46 Options (\$0.09, 17/01/2024) |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | (a) ME1OE Options issued under the bonus option issue made to all eligible shareholders. Refer to Prospectus released 31 October 2023 (and Supplementary Prospectus released 6 November 2023) for further information. (b) ME1OD Options issued free-attaching to Shares issued in lieu of Director Fees. Refer to Resolution 11 of the Notice of Meeting dated 12 September 2023. |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|---|-----|
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |

Part 3 – ⁺Closed period

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|--------------------------------|
| Name of entity | Melodiol Global Health Limited |
| ABN | 89 609 406 911 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|-----------------|
| Name of Director | Jodi Scott |
| Date of last notice | 3 November 2023 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|---|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | N/A |
| Date of change | (a) 13 November 2023 (b) 17 November 2023 |
| No. of securities held prior to change | 220,769,990 Fully Paid Ordinary Shares |
| Class | (a) ME1OE Listed Options (\$0.006, expiring 13/11/2028) (b) Fully Paid Ordinary Shares |
| Number acquired | (a) 11,038,499 ME1OE Listed Options (\$0.006, expiring 13/11/2028) (b) 44,972,436 Fully Paid Ordinary Shares |
| Number disposed | Nil |

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

| | |
|---|--|
| <p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p> | <p>(a) ME1OE Options issued for nil consideration under the bonus option issue made to all eligible shareholders. Refer to Prospectus released 31 October 2023 (and Supplementary Prospectus released 6 November 2023) for further information.</p> <p>(b) Shares issued in lieu of cash repayment of Ms Scott's US\$273,481.03 loan to the Company's subsidiary, Sierra Sage Herbs, LLC. Refer to Resolution 37 of the Notice of Meeting dated 12 September 2023 for further information.</p> |
| <p>No. of securities held after change</p> | <p>265,742,426 Fully Paid Ordinary Shares 11,038,499 ME1OE Listed Options (\$0.006, expiring 13/11/2028)</p> |
| <p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p> | <p>(a) Options issued under the bonus option issue made to all eligible shareholders. Refer to Prospectus released 31 October 2023 (and Supplementary Prospectus released 6 November 2023) for further information.</p> <p>(b) Issue of Shares in lieu of repayment of a loan. Refer to Resolution 37 of the Notice of Meeting dated 12 September 2023 for further information.</p> |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|------------|
| <p>Detail of contract</p> | <p>N/A</p> |
| <p>Nature of interest</p> | <p>N/A</p> |
| <p>Name of registered holder (if issued securities)</p> | <p>N/A</p> |
| <p>Date of change</p> | <p>N/A</p> |
| <p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p> | <p>N/A</p> |
| <p>Interest acquired</p> | <p>N/A</p> |
| <p>Interest disposed</p> | <p>N/A</p> |
| <p>Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation</p> | <p>N/A</p> |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|------------------------------|-----|
| Interest after change | N/A |
|------------------------------|-----|

Part 3 – ⁺Closed period

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|--------------------------------|
| Name of entity | Melodiol Global Health Limited |
| ABN | 89 609 406 911 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|------------------|
| Name of Director | Micheline MacKay |
| Date of last notice | 3 November 2023 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|--|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | N/A |
| Date of change | 13 November 2023 |
| No. of securities held prior to change | 3,119,667 Fully Paid Ordinary Shares |
| Class | ME1OE Listed Options (\$0.006, expiring 13/11/2028) |
| Number acquired | 155,983 |
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | Issued for nil consideration under the bonus option issue made to all eligible shareholders. Refer to Prospectus released 31 October 2023 (and Supplementary Prospectus released 6 November 2023) for further information. |
| No. of securities held after change | 3,119,667 Fully Paid Ordinary Shares 155,983 ME1OE Listed Options (\$0.006, expiring 13/11/2028) |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

| | |
|---|--|
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issued under the bonus option issue made to all eligible shareholders. Refer to Prospectus released 31 October 2023 (and Supplementary Prospectus released 6 November 2023) for further information. |
|---|--|

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|-----|
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |

Part 3 – ⁺Closed period

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

⁺ See chapter 19 for defined terms.